Glenn Crater - Publications, H-index & Citations

Glenn Crater

LLC

27H指数

130论文数

2.2K被引数

收录论文 45

发表时间

PPIs and COPD Exacerbations 质子泵抑制剂与慢性阻塞性肺疾病急性加重

Chest

IF8.6

2026-07-08

PREAI

Glenn D. Crater

Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial Monlunabant在成人体重肥胖和代谢综合征中的研究：2a期临床试验的开放标签扩展研究

diabetes, obesity and metabolism

IF0

2026-03-24

OAAI

Filip K. Knop MD; George Kunos MD; Dror Dicker MD; Jean-Sebastien Paquette MD; Louis Aronne MD; Oscar Birkhan MD; Ofir Frenkel MD; Thomas Holst-Hansen PhD; Karine Lalonde MSc; Glenn Crater MD; for the trial investigators

A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease 一项双盲、随机、安慰剂对照的2期试验，考察了monlunabant在糖尿病肾病患者中的有效性和安全性。

Kidney International

IF12.6

2026-03-20

OAAI

David Z.I. Cherney; Karen Bonefeld; Glenn Crater; Jamie P. Dwyer; Ofir Frenkel; Julie F. Furberg; Filip K. Knop; George Kunos; Karine Lalonde; David C. Wheeler; Christoph Wanner

Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial 莫仑那班在肥胖和代谢综合征成人中的疗效与安全性：一项双盲、随机、安慰剂对照、2a期试验

The Lancet Diabetes & Endocrinology

IF41.8

2025-09-29

PREAI

Filip K Knop; George Kunos; Dror Dicker; Jean-Sebastien Paquette; Louis Aronne; Ofir Frenkel; Thomas Holst-Hansen; Karine Lalonde; Jisoo Lee; Glenn Crater

Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study

DIABETES OBESITY & METABOLISM

IF5.7

2023-11-08

OAAI

Crater, Glenn D.; Lalonde, Karine; Ravenelle, Francois; Harvey, Michael; Despres, Jean-Pierre

Effects of CB1 Antagonist INV202 in Patients with Metabolic Syndrome-A Randomized, PlaceboControlled, Double-Blind Phase 1B Study

DIABETES

IF7.5

2023-06-20

PREAI

Crater, Glenn D.; Ravenelle, Francois; Lalonde, Karine; Despres, Jean-Pierre

INV-101, a cannabinoid receptor-1 inverse agonist, reduces fibrosis in a bleomycin mouse model of IPF

EUROPEAN RESPIRATORY JOURNAL

IF21

2022-12-01

PREAI

Crater, G. D.; Gaucher, G.; Harvey, M.; Ravenelle, F.

Lung deposition of inhaled once-daily long-acting muscarinic antagonists via standard jet nebulizer or dry powder inhaler, measured using functional respiratory imaging, in patients with chronic obstructive pulmonary disease

therapeutic advances in musculoskeletal disease

IF3

2022-03-02

OAAI

Crater, Glenn D.; Johnson, Karmon; Ward, Jonathan; Backer, Jan De

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

EUROPEAN RESPIRATORY JOURNAL

IF21

2021-07-01

OAAI

Singh, Dave; Bogus, Maxim; Moskalenko, Valentyn; Lord, Robert; Moran, Edmund J.; Crater, Glenn D.; Bourdet, David L.; Pfeifer, Nathan D.; Woo, Jacky; Kaufman, Elad; Lombardi, David A.; Weng, Emily Y.; Nguyen, Tuan; Woodcock, Ashley; Haumann, Brett; Saggar, Rajeev

Lung deposition of two bronchodilators in subjects with (COPD) when administered via standard jet nebulizer or Handihaler® using functional respiratory imaging (FRI)

EUROPEAN RESPIRATORY JOURNAL

IF21

2020-10-28

PREAI

Crater, Glenn; Moran, Edmund; Ward, Jonathan; Belmans, Dennis; Van Holsbeke, Cedric

Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials 无论慢性阻塞性肺疾病 (COPD) 的基线症状状态如何，revepenacin (REV) 均可改善健康状况和呼吸困难: 3期试验的事后分析

EUROPEAN RESPIRATORY JOURNAL

IF21

2020-10-28

PREAI

Ferguson, Gary T.; Siler, Thomas M.; Lombardi, David A.; Crater, Glenn

Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236

EUROPEAN RESPIRATORY JOURNAL

IF21

2020-10-28

PREAI

Gordon, Emma; Kaufman, Elad; Sana, Reuben; Mcnamara, Alexander; Pfeifer, Nathan; Moran, Edmund J.; Crater, Glenn D.; Kleinschek, Melanie A.; Woo, Jacky; Southworth, Thomas; Scott, Thomas; Singh, Dave

IMPROVEMENTS IN HEALTH STATUS WITH REVEFENACIN: A POST HOC ANALYSIS OF ST GEORGE'S RESPIRATORY QUESTIONNAIRE IN PATIENT SUBGROUPS FROM REPLICATE PHASE 3 TRIALS

CHEST

IF8.6

2020-10-01

OAAI

Siler, Thomas; Donohue, James; Lombardi, David; Crater, Glenn

Peak Inspiratory Flows Defining Repeatability Limits and a Predictive Equation for Different Inhalers 定义不同吸入器的重复性极限和预测方程的峰值吸气流量

CHEST

IF8.6

2020-10-01

OAAI

Barnes, Chris N.; Mahler, Donald A.; Ohar, Jill A.; Lombardi, David A.; Crater, Glenn D.